Author Archives: admin

American Academy of Stem Cell Physicians is Hosting an FDA Safety Panel, Session is Now Free to the Public – Yahoo Finance

By adminAugust 1, 2020Stem Cell Treatment

Important FDA Safety Panel discussion open and free to the public Aug. 1-3, 2020

MIAMI, July 29, 2020 /PRNewswire/ --An FDA Safety Panel discussion will be held virtually by the American Academy of Stem Cell Physicians (AASCP) Aug.1-3, 2020, with guest speakerFDA Director Dr. Peter Marks. This is a highly anticipated session which will discuss the growing safety concerns of the industry.

The AASCP has recently created guidelines thatare current safety recommendations given to physicians who are using biologics in their medical practice. A highly anticipated and sought-after Safety StandardsPanel session will be hosted VIRTUALLY by AASCP on Aug. 1-3. 2020; guest of honor isDr. Peter Marks, FDA Director of CBER. The sessions normally are closed to the public but this particular SafetyStandard Panel discussion will be open and free to the public, covering the growing safety concerns of the industry.

The Safetypanel discussion will discuss advancements in development, manufacturing and delivery of safe and effective regenerative cell therapies through policy development, consensus and advocacy. The Safety Panel discussion willbringtogether experts and stakeholders to gain consensus on and advocate for policies that will advance the science and the field, including those focused on promoting clinical research, assuring the adoption of consensus standards to promote safety and quality, building capacity and expertise within the workforce, and establishing a national outcomes database to advance the science, promote improvements in quality and safety, and inform regulatory and patient decision-making.

According to AASCP, if physicians are using biologics in their practice, whether they are using SVF, PRP, bone marrow, UCB, amniotic products, exosomes, xenograftsor peptides, there are key considerations to take into account to achieve the best safety for their patients. The AASCP also recommends communication with the Chief Scientific Officer from the laboratory they work with. AASCP advises that just talking to a sales agent is not sufficient enough when determining the quality of products for their patients. Sales agents typically do not have a medical or scientific background.

The President for the AASCP, Dr. Martin Dayton,said earlier: "The American Academy of Stem Cell Physicians is a group of physicians, scientists and researchers who collectively represent the most authoritativenon-federal group advocating for guidelines and education on stem cell therapy and regenerative medicine. AASCP members are experts within all fields of stem cell therapy fromSVF, BM, UCB, Exosomes, Peptides, Xenografts, Allografts and Amniotic Fluids and are considered the most experienced leaders for proper advocacy in the field. The AASCP is involved directly with other authorities within the field and seeks only to bring knowledge and awareness for the ever-growing regenerative medicine industry.My hope is that the SafetyPanel discussion on Aug. 1-3, 2020, is to help get rid of the bad actors that are damaging the field for everyone."

The importance of this virtual conference coincides with the ever-emerging growthof the globalregenerative medicine marketwhich is expected to reachUSD 79.8 billionby 2024, at aCAGR of 20.5%from 2018 to 2024. Factors driving the growth of the market areincreasing prevalence of degenerative and chronic diseases, technological advancements in nanotechnology, bioengineering and stem cell therapy, and increasing geriatric population across the globe.TheAASCP virtual meeting is set for Aug. 1, 2020.List of speakers is available at http://www.aascp.net.

Due to COVID-19, the meeting will take place virtually.Thisis an effective way to ensure that everyone that wishes to participate, but cannot travel, can. Students, educators and physicians will not have to miss out on all the important topics that AASCP has on the pipeline.

Virtual Workshop Lecturers will virtually demonstrate their techniques live via their professional locations. These virtualinteractive workshops will feature small participant-to-instructor ratios with a customized curriculum focusing on developing hands-on skills. Each technique will be taught by experts in the field, using didactic sessions with dynamic multimedia presentations, live demonstrations and scanning on live models, as well as phantoms.

AASCP spokesmanDr. A.J.Farshchianexplains, "We will duplicate everything we did in our past meetings such as offer CME credits, have lectures, workshops, discuss FDA safety standards, have board examinations and a virtual graduation ceremony. AASCP is offering this virtual meeting so that nobody misses out on the education."

To join the free session via Zoom, please click on the link below at 11a.m. this Saturday.

Join Zoom Meeting: https://aascp.zoom.us/j/4150937630

Meeting ID: 415 093 7630

The American Academy of Stem Cell Physicians (AASCP) is a non-profit organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatment, and prevention of disease related to or occurring within the human body. Secondarily, the AASCPaims to serve as an educational resource for physicians, scientists, and the public in diseases that can be caused by physiological dysfunction that isameliorable to medical treatment.

For further information, please contact MarieBarbaat AASCP at 305-891-4686or visit us at http://www.aascp.net.

Related Images

virtual-conference-aug-1-3-2020.jpeg Virtual Conference Aug. 1-3, 2020

aascp.png AASCP

Amniotic Fluid Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2018 – 2026 – Market Research Correspondent

By adminAugust 1, 2020Stem Cell Treatment

With having published myriads of reports, PMR imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts deliver reports with accurate data extracted from trusted sources. We ride the wave of digitalization facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available 24/7 to provide tailored business solutions to the clients.

In this new business intelligence report, PMR serves a platter of market forecast, structure, potential, and socioeconomic impacts associated with the global Amniotic Fluid Stem Cell Therapy market. With Porters Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Amniotic Fluid Stem Cell Therapy market.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/23101

The Amniotic Fluid Stem Cell Therapy market report has been fragmented into important regions that showcase worthwhile growth to the vendors Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2) and region 3 (Country 1, Country 2). Each geographic segment has been assessed based on supply-demand status, distribution, and pricing. Further, the study provides information about the local distributors with which the market players could create collaborations in a bid to sustain production footprint.

key players operating in global amniotic fluid stem cell therapy market are Stem Shot, Provia Laboratories LLC, Thermo Fisher Scientific Inc. Mesoblast Ltd., Roslin Cells, Regeneus Ltd. etc. among others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/23101

What does the Amniotic Fluid Stem Cell Therapy market report contain?

Readers can get the answers of the following questions while going through the Amniotic Fluid Stem Cell Therapy market report:

And many more

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/23101

Here is the original post:
Amniotic Fluid Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2018 - 2026 - Market Research Correspondent

Rockies vs. Athletics – Game Recap – July 28, 2020 – ESPN

By adminAugust 1, 2020Platelet Rich Plasma Injections

OAKLAND, Calif. -- Sam Hilliard homered for the first time this season, Antonio Senzatela pitched out of an early jam on his way to a rare road win, and the Colorado Rockies beat the Oakland Athletics 8-3 Tuesday night.

Charlie Blackmon had two hits, David Dahl drove in a pair of runs and Nolan Arenado made up for an uncharacteristic fielding error with a single and sacrifice fly to help the Rockies to their third straight win following an opening day loss to Texas.

"We've got a good pitching staff always and this year we've been doing good," Senzatela said. "We were just working for that in the offseason, even through the quarantine. I think we deserve this."

Hilliard was hitless going into the day before doubling off A's starter Daniel Mengden in the second and then homering in the fourth. Hilliard, who homered in his major league debut last August, laced a 2-2 pitch into the right-field stands after Raimel Tapia singled.

"Sam's blast, the breaking ball in the seats was a great swing," Rockies manager Bud Black said. "I like the double the other way. We saw Sam do that a number of times last year, take pitches away from him, hit them to left field. The home run gave us a big lift."

Senzatela worked himself into an early jam but got Oakland slugger Khris Davis to pop out with the bases loaded in the first on the way to his first win on the road since July 5, 2019. The right-hander had dropped five straight away from home since then.

Senzatela (1-0) allowed two runs (one earned) and six hits in five innings. He walked three and struck out three.

"I threw too many pitches in the first inning but I just put on myself, `I need to make it through five to give the team a chance to win,' and I did it," Senzatela said.

Tyler Kinley, Daniel Bard and Carlos Estevez combined to two-hit the A's over the final four innings.

Ramon Laureano had two hits and Mark Canha added a sacrifice fly for the A's, who were attempting to go 4-1 for the first time since 2010.

Oakland manager Bob Melvin had been hopeful of resting his taxed bullpen but didn't get the chance after Mengden (0-1) lasted four innings and gave up three runs on five hits.

"Strike one can be a problem for him sometimes," Melvin said. "He tries to be a little too fine at times. It's getting the pitch count down and trying to get the other team to put the ball in play earlier in the count."

The Rockies tacked on a pair in the fifth with four consecutive one-out hits and a sacrifice fly off A's reliever Jordan Weems in his major league debut. They scored three more in the eighth.

MILESTONE, BUT NO HITS

Davis moved into second place in games played by A's designated hitters but continued to struggle at the plate. He struck out twice, popped up and hit into a double play in four at-bats, dropping the Oakland slugger to 0 for 15 this season.

"I've said all along that leashes can be a little bit shorter when you struggle in 60 games," Melvin said. "It's like being in August right now. Some of the guys who have track records deserve a little bit of a longer leash. He's been really good for us over the years."

The game marked the 356th for Davis as the A's DH, moving him past Mitchell Page on the franchise list. Davis will have to wait until next season to break Dave Kingman's mark of 428.

TRAINER'S ROOM

Athletics: Mengden pitched in a game for the first time since undergoing elbow surgery in February. He was moved into the rotation as left-hander A.J. Puk deals with a strained throwing shoulder that landed him on the injured list to start the season and required cortisone and platelet-rich plasma injections. . T.J. McFarland, Jake Diekman and Yusmeiro Petit, all of whom pitched three times in Oakland's first four games, were rested.

UP NEXT

The two-game series ends Wednesday afternoon when Oakland's Frankie Montas (0-0, 2.25 ERA) makes his second start of the season against Colorado's German Marquez (0-1, 1.59) in a matchup of right-handers. Marquez's loss on opening day was his first in 16 interleague starts.

---

More AP MLB: https://apnews.com/MLB and https://twitter.com/AP-Sports

Global Market Trends in the Cell and Gene Therapy Tools and Reagents Market 2020-2024 – GlobeNewswire

By adminAugust 1, 2020Stem Cell Treatment

July 31, 2020 07:48 ET | Source: Research and Markets

Dublin, July 31, 2020 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Tools, and Reagents: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Gene and cell therapy are emerging as important tools to treat human health. Techniques such as CAR-T therapy have emerged as key ways of treating many different types of cancers. The promise of gene therapy using technologies such as CRISPR is starting to be realized in clinical trials, and markets are scaling up to treat other diseases as well, particularly rare gene-based diseases. As these therapies are coming to the fore, a new market for tools to develop these therapies using standard methodologies is emerging. This report will cover what those tools are, how they impact the larger life science tools market, and how they will evolve over the next five years.

The scope of this study encompasses an investigation of the market's cell and gene therapy tools such as GMP proteins, media, cell separation and activation reagents, viral and non-viral, cytokine release syndrome monitoring products, GMP antibodies, leukapheresis instrumentation, immunoassays (multiplex and singleplex) and bioreactors. This research analyzes each tool type, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed. The report analyzes the industry on a worldwide basis, from both application and demand perspectives, in the major regions of the world.

The Report Includes:

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Market Breakdown by Region

Chapter 5 Market Breakdown by End User

Chapter 6 Government Regulations

Chapter 7 Patent Review/New Developments

Chapter 8 Analysis of Market Opportunities

Chapter 9 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/86txdi

About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Formats available:

Go here to read the rest:
Global Market Trends in the Cell and Gene Therapy Tools and Reagents Market 2020-2024 - GlobeNewswire

Stem Cell Market Analysis and Forecast by Rapid Growth Rate 2020 Value Share Analysis by Regions, Industry Size, Key Insights till 2024 – Bulletin…

By adminAugust 1, 2020Embryonic Stem Cells

International Stem Cell Corporation

Report Highlights:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13999718

Key Market Trends:

Oncology Disorders Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period

Cancer has a major impact on society in the United States and across the world. As per the estimation of National Cancer Institute, in 2018, 1,735,350 new cases of cancer were anticipated to get diagnosed in the United States, and 609,640 deaths were expected from the disease. This increasing medical burden is due to population growth. Bone marrow transplant or stem cell transplant is a treatment for some types of cancers, like leukemia, multiple myeloma, multiple myeloma, neuroblastoma, or some types of lymphoma.

Embryonic stem cells (ESC) are the major source of stem cells for therapeutic purposes, due to their higher totipotency and indefinite lifespan, as compared to adult stem cells with lower totipotency and restricted lifespan. However, the use of ESCs for research and therapeutic purposes is restricted and prohibited in many countries throughout the world, due to some ethical constraints. Scientists from the University of California, Irvine, created the stem cell-based approach to kill cancerous tissue while preventing some toxic side effects of chemotherapy by treating the disease in a more localized way.

Although the market shows positive growth, due to the growing focus of stem cell-based research that can further strengthen the clinical application, its expensive nature for stem cell therapy may still hamper its growth.

North America Captured The Largest Market Share and is Expected to Retain its Dominance

North America dominated the overall stem cell market with the United States contributing to the largest share in the market. In 2014, the Sanford Stem Cell Clinical Center at the University of California, San Diego (UCSD) Health System, announced the launch of a clinical trial, in order to assess the safety of neural stem cell-based therapy in patients with chronic spinal cord injury. Researchers hoped that the transplanted stem cells may develop into new neurons that could replace severed or lost nerve connections, and restore at least some motor and sensory functions. Such numerous stem cell studies across the United States have helped in the growth of the stem cell market.

The Report Covers:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/13999718

Detailed TOC of Stem Cell Market Report 2020-2024:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Increased Awareness about Umbilical Stem Cell 4.2.2 Increase in the Approval for Clinical Trials in Stem Cell Research 4.2.3 Growing Demand for Regenerative Treatment Option 4.2.4 Rising R&D Initiatives to Develop Therapeutic Options for Chronic Diseases 4.3 Market Restraints 4.3.1 Expensive Procedures 4.3.2 Regulatory Complications 4.3.3 Ethical and Moral Framework 4.4 Industry Attractiveness- Porters Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Product Type 5.1.1 Adult Stem Cell 5.1.2 Human Embryonic Cell 5.1.3 Pluripotent Stem Cell 5.1.4 Other Product Types 5.2 By Therapeutic Application 5.2.1 Neurological Disorders 5.2.2 Orthopedic Treatments 5.2.3 Oncology Disorders 5.2.4 Diabetes 5.2.5 Injuries and Wounds 5.2.6 Cardiovascular Disorders 5.2.7 Other Therapeutic Applications 5.3 By Treatment Type 5.3.1 Allogeneic Stem Cell Therapy 5.3.2 Auto logic Stem Cell Therapy 5.3.3 Syngeneic Stem Cell Therapy 5.4 By Banking Service and Technology 5.4.1 Stem Cell Acquisition and Testing 5.4.2 Cell Production 5.4.3 Expansion 5.4.4 Sub-culture 5.4.5 Cryopreservation 5.5 By Type of Banking 5.5.1 Public 5.5.2 Private 5.6 Geography 5.6.1 North America 5.6.1.1 US 5.6.1.2 Canada 5.6.1.3 Mexico 5.6.2 Europe 5.6.2.1 UK 5.6.2.2 Germany 5.6.2.3 France 5.6.2.4 Italy 5.6.2.5 Spain 5.6.2.6 Rest of Europe 5.6.3 Asia-Pacific 5.6.3.1 China 5.6.3.2 Japan 5.6.3.3 India 5.6.3.4 Australia 5.6.3.5 South Korea 5.6.3.6 Rest of Asia-Pacific 5.6.4 Middle East & Africa 5.6.4.1 GCC 5.6.4.2 South Africa 5.6.4.3 Rest of Middle East & Africa 5.6.5 South America 5.6.5.1 Brazil 5.6.5.2 Argentina 5.6.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Osiris Therapeutics Inc. 6.1.2 Pluristem Therapeutics Inc. 6.1.3 Thermo Fisher Scientific 6.1.4 Qiagen NV 6.1.5 Sigma Aldrich Corporation 6.1.6 Becton, Dickinson and Company 6.1.7 Stem Cell Technologies Inc. 6.1.8 AllCells LLC 6.1.9 Miltenyi Biotec 6.1.10 International Stem Cell Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Lower Extremity Bone Fixation Screws Market Share Value 2020 Industry Top Players, Trends, Global Growth Rate by Size Expansion Strategies by 2026 Report Includes COVID-19 Analysis

Managed Mobility Services Market Size Analysis with Industry Share 2020: Industry Trend, Business Growth, Segmentation, Competitors, and Forecast Details for 2024 | Industry Research.co

Cotton Balls Market Share Value 2020 Industry Top Players, Trends, Global Growth Rate by Size Expansion Strategies by 2026 Report Includes COVID-19 Analysis

Thin Film SMD Resistors Market Growth Rate by Share 2020-2026 | Revenue Forecast by Product Type, Applications and Regions and COVID-19 impact on Global Industry

Ammonium Carbonate Market Key Developments by Global Size, Emerging Trends, Industry Analysis, Growth Status of Manufacturers, and Product Specification Forecast to 2020-2024

Medicinal Shampoo Market Share Value 2020 Industry Top Players, Trends, Global Growth Rate by Size Expansion Strategies by 2026 Report Includes COVID-19 Analysis

FDA Approves Tafasitamab-cxix in Combination With Lenalidomide for the Treatment of DLBCL – Pharmacy Times

By adminAugust 1, 2020Stem Cell Treatment

FDA Approves Tafasitamab-cxix in Combination With Lenalidomide for the Treatment of DLBCL

A humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, tafasitamab-cxix received accelerated approval based on overall response rate (ORR). Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Globally, DLBCL is the most common type of non-Hodgkin lymphoma in adults. The aggressive disease is characterized by rapidly growing masses of malignant B-cells in the lymph nodes, spleen, liver, bone marrow or other organs, and about 1 in 3 patients do not respond to initial therapy or relapsing thereafter.In the United States, approximately 10,000 patients are diagnosed with relapsed or refractory DLBCL who are not eligible for ASCT, each year.

The FDA approval was based on data from the MorphoSys-sponsored Phase 2 L-MIND study, an open label, multicenter, single arm trial of tafasitamab-cxix in combination with lenalidomide as a treatment for adult patients with relapsed or refractory DLBCL. Results from the study showed an ORR of 55% (primary endpoint), including a complete response (CR) rate of 37%, and a partial response rate (PR) of 18%. The median duration of response (mDOR) was 21.7 months (key secondary endpoint).

Warnings and precautions for tafasitamab-cxix included infusion-related reactions (6%), serious or severe myelosuppression including neutropenia (50%), thrombocytopenia (18%), and anemia (7%); infections (73%), and embryo-fetal toxicity. Neutropenia led to treatment discontinuation in 3.7% of patients. The most common adverse reactions ( 20%) were neutropenia, fatigue, anemia, diarrhea, thrombocytopenia, cough, pyrexia, peripheral edema, respiratory tract infection, and decreased appetite.

The FDA previously granted Fast Track and Breakthrough Therapy Designation for the tafasitamab-cxix and lenalidomide combination in treatment of relapsed or refractory DLBCL. FDA.

Tafasitamab-cxix is expected to be commercially available in the United States shortly, according to MorphoSys and Incyte, which plan to co-commercialize this therapy in the US. Incyte has exclusive commercialization rights outside the US.

REFERENCE

FDA Approves Monjuvi(tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) [news release]. Planegg & Munich, Germany, and Wilmington, DE; July 31, 2020: MorphoSys and Incyte.https://www.businesswire.com/news/home/20200731005497/en.

View original post here:
FDA Approves Tafasitamab-cxix in Combination With Lenalidomide for the Treatment of DLBCL - Pharmacy Times

Church Point Police Captain dies from COVID-19 complications: ‘Go and protect the heavens, my dearest friend’ – The Advocate

By adminAugust 1, 2020Stem Cell Medical Center

A Church Point Police Department captain has died from serious medical complications after contracting COVID-19.

Church Point Police Chief Dale Thibodeaux shared news of Capt. Kevin Trahans death in a post from the departments Facebook page Saturday morning. Thibodeaux wrote that Trahan returned to the job in April after a period of absence to receive a bone marrow or stem cell transplant at MD Anderson Cancer Center in Houston to ward off an unspecified cancer.

He later contracted the virus while on the job, the chief said.

Success! An email has been sent with a link to confirm list signup.

Error! There was an error processing your request.

In a July 22 post on his personal Facebook, Thibodeaux said that the department and Trahans family were asking for prayers while Trahan was hospitalized in the intensive care unit. After being diagnosed with COVID-19, Trahan also suffered from pneumonia, clots in both legs and suffered strokes while sedated on a ventilator, the chief relayed from Trahans son.

Trahan died around 10:30 p.m. Friday at a Monroe hospital and Church Point police officers will be escorting his body back to Acadia Parish Saturday, Thibodeaux said.

Trahan, 59, leaves behind his wife, Brenda, who also works for the Church Point Police Department, three adult children, two stepdaughters, two grandchildren and a step-granddaughter, Thibodeaux said.

He tried to help everyone and would give you the shirt off his back if he could. Capt. Trahan was also a dedicated officer and always gave a hundred percent all the timeWith all Capt. Trahan fought through and continued to do his job on a professional level, he was and always will be a true hero, Thibodeaux wrote.

Go and protect the heavens, my dearest friend, family and my brother. The Lord needs you right now more than we do, I guess. You will be missed dearly.

Trahan served in law enforcement for roughly 30 years as a deputy with the Acadia Parish Sheriffs Office and an officer with the Church Point Police Department, the chief said. When Thibodeaux assumed the chief position, Trahan became his right hand man.

While close from their time in law enforcement, the two men were more than brothers in blue they were also family. Trahan was married to Thibodeauxs sister-in-law, he said.

Trahan was generous, kind, determined, hardworking and had a way of talking to people that reached them, Thibodeaux said. He was passionate about helping people and serving the community; even after his treatment at MD Anderson, it was impossible to keep him assigned to desk duty because he was determined to give his best effort on patrol, the chief said.

Everyone who knew him liked him.

His personality was something else. Theres no way he didnt walk into a room and liven it up in some kind of way, Thibodeaux said.

Other law enforcement officers shared condolences online and remembered Trahans commitment to serving the community and mentoring other officers.

It was an honor to know and learn from such a great man. Captain Kevin Trahan was genuinely a good guy who was beyond willing to teach and show beginning officers the way to become a good officer. In the two years I've been with the police department I have gotten to ride and sit with him many times and just simply listen to his stories and learn many things. He will definitely be missed, Church Point Police Officer Holden Hare shared on Facebook.

I received some of the best advice from you when I started this career and I will forever hold on to that advice and guidance youve given me. May you finally Rest In Peace as your legacy will never be forgotten, Hunter Hare wrote.

See original here:
Church Point Police Captain dies from COVID-19 complications: 'Go and protect the heavens, my dearest friend' - The Advocate

Why Superman 5 With Christopher Reeve Never Happened – Screen Rant

By adminAugust 1, 2020Stell Cell Research

Despite Superman IV: The Quest for Peace's failure, there was a hope that Christopher Reeve would return for Superman V. Here's why it didn't happen.

Superman V never happened, and there are ample reasons why Christopher Reeve never performed as the Man of Steel again after the failure of 1987's Superman IV: The Quest for Peace. Christopher Reeve played Superman for a decade, starting with Richard Donner's 1978 Superman: The Movie and continuing on with Richard Lester's Superman II and Superman III. For a generation of fans, Reeve's earnest Superman is the definitive version and he remains the standard by which all other actors who have played the Man of Steel are judged.

The first two Superman movies, which were produced by Alexander and Ilya Salkind, were global blockbusters. Donner's original film innovated the special effects technology that made audiences believe Superman could really fly, and the first two films are wildlyimaginative and heartfelt adventures that pioneered the modern superhero movie. Unfortunately, Superman III, which co-starred the comedian Richard Pryor, was a disappointment; it was made with a slashed budget, grossed less than its predecessors, and the third film received mixed reviews from critics and audiences, despite novel ideas like an evil Superman fighting his good side, Clark Kent. After Superman III and the subsequent failure of the Supergirl spinoff in 1984 (which Reeve refused to appear in), the Salkinds decided the Superman movies had run their course and they sold the rights to Menahem Golan and Yoram Globus of Cannon Films.

Related: What Superman Returns 2 Was Supposed To Be About (& Why It Didn't Happen)

However, the Cannon Films-produced Superman IV: The Quest for Peace was a disaster. Cannon had numerous films under production and attempted to make Superman IV for even less money than Superman III, shortchanging everything from the sets to the obviously sub-par visual effects. Despite a socially-relevant story partly conceived by Reeve where Superman tries to rid the world of nuclear weapons, and the return of Gene Hackman as Lex Luthor, Superman IV was an embarrassment to everyone involved and grossed a paltry $36-million worldwide. With Superman IV crashing and burning, there was virtually no chance Reeve would agree to return for Superman V.

Despite their failure, Cannon Films did intend to make Superman V at one point and earmarked Reeve to return as the Man of Steel. Cannon's plan was to take an even cheaper route and cobble together 45 minutes of unused footage from Superman IV as the basis for a fifth movie. However, nothing came of it, and Cannon, which was in the red after numerous cinematic failures, folded in the early 1990s. The movie rights to Superman reverted back to the Salkinds, but they created a Superboy TV series instead of a movie.

Still, in 1991, screenwriter Cary Bates pitched an idea for Superman V to Alexander and Ilya Salkind, which would star Christopher Reeve once more. Bates' plan was to ignore Superman III and IV (something Bryan Singer also chose to do when he directed Superman Returns in 2006) and pit the Man of Steel against Brainiac in the Bottled City of Kandor. But at this point in the early '90s, the Salkinds were producing Christopher Columbus: The Discovery, which ran massively overbudget and ultimately lost the father-son producing team $40-million. The Salkinds quit the movie business afterward and the Superman movie rights reverted to Warner Bros. After Superman IV failed in 1987, it would take 19 years for the Man of Steel to return to the big screen in Superman Returns,despite an infamous attempt by Warners to make Superman Lives starring Nicolas Cage and directed by Tim Burton.

In 1995, Christopher Reeve suffered a tragic accident when he was thrown from his horse during an equestrian competition. The accident left Reeve a quadriplegic, although he heroically persevered. Following his rehabilitation, Reeve became a champion for stem cell research, spinal cord research, and people with disabilities, establishing the Christopher Reeve Foundation (which is now the Christopher and Dana Reeve Foundation). Reeve also returned to acting and he even appeared in season 2 of Smallville, where he passed the torch to the small screen's newest Man of Steel, Tom Welling. Christopher Reeve died on October 10, 2004, but the final years of his life proved the real-life man was more heroic than appearing in Superman V would ever allow him to be.

Next:Kingdom Come Superman Becomes [SPOILER] At The End Of Crisis on Infinite Earths

Scott Disick 'Flirting' with Kourtney Kardashian After Sofia Richie Split

John has been writing about what he likes - movies, TV, comics, etc. - for over a decade. He's worked in movies and rubbed shoulders with big names but somehow forgot to ask for money a lot of the time - hence, he is happy to be with Screen Rant. John can be found @BackoftheHead, counts a Black Canary and an Agent of S.H.I.E.L.D. among his friends, believes (correctly) that Superman is stronger than the Hulk, and he is a friend to all talking gorillas.

Excerpt from:
Why Superman 5 With Christopher Reeve Never Happened - Screen Rant

Cryopreservation Media Market Highly Favourable with new Demand to the Growth Rate by 2025 – Market Research Posts

By adminAugust 1, 2020Stem Cell Medicine

AMA Research added a comprehensive research document of 200+ pages on Cryopreservation Media market with detailed insights on growth factors and strategies. The study segments key regions that includes North America, Europe, Asia-Pacific with country level break-up and provide volume* and value related cross segmented information by each country. Some of the important players from a wide list of coverage used under bottom-up approach are Thermo Fisher Scientific, Inc. (United States), Osiris Therapeutics, Inc (United States), Sigma-Aldrich Corporation (United States), VWR Corporation (United States), Biolife Solutions, Inc. (United States), Lifeline Scientific, Inc. (United States), Cesca Therapeutics, Inc. (United States), BioCision, LLC (United States), Core Dynamics, Ltd. (Israel), Custom Biogenic Systems, Inc. (United States), So-Low Environmental Equipment Co., Inc. (United States), Princeton Cryotech, Inc. (United States).

Request a sample report @ https://www.advancemarketanalytics.com/sample-report/16856-global-cryopreservation-media-market

Cryopreservation Media is designed to maintain and preserve cells at low environmental temperature and decreases the risk of infection by microbes and other cell types. It provides a safe environment for cells and tissues while undergoing freezing, storage and thawing process. This is specially framed media which contains a defined serum substitute as well as an improved concentration of a cryopreservative that increases the recovery and viability of healthy cells compared to conventional freezing media.

Market Segmentation & Scope

Study by Type (Lysogenic broth, Protein-free media, Specialty media, Serum-free media, Chemically-defined media), Application (Biobanks, Gene Banks, Hospitals, Tissue engineering, Stem cell technologies, Therapeutic Applications, Cancer and Research Applications, Clinical Trials, Others), Bio-specimens Types (Human Tissue Samples, Stem Cells, Organs, Others)

Global Cryopreservation Media Market Report offers a detailed overview of this market and discusses the dominant factors affecting the growth of the market. The impact of Porters five armies on the market over the next few years has been discussed for a long time in this study. We will also forecast global market size and market outlook over the next few years.

Types of Products, Applications and Global Cryopreservation Media Market Report Geographical Scope taken as the Main Parameter for Market Analysis. This Research Report Conducts an assessment of the industry chain supporting this market. It also provides accurate information on various aspects of this market, such as production capacity, available production capacity utilization, industrial policies affecting the manufacturing chain and market growth.

Avail 30-50% Discount on various license type on immediate purchase @ https://www.advancemarketanalytics.com/request-discount/16856-global-cryopreservation-media-market

A View on Influencing Trends:

Adoption in Conserving Cord Blood Stem Cells of Newborns

The increasing Trend of Cryopreservation of Eggs and Embryos

Growth Drivers in LimelightIncreasing Healthcare Expenditure

Increasing R&D Investments

Advancement in Biobanking

Advances in Regenerative Medicine

Challenges that Market May Face:Lack of Consumer Awareness Regarding Cryopreservation Media

The report concludes with in-depth details on the business operations and financial structure of leading vendors in the Global Cryopreservation Media market report, Overview of Key trends in the past and present are in reports that are reported to be beneficial for companies looking for venture businesses in this market. Information about the various marketing channels and well-known distributors in this market was also provided here. This study serves as a rich guide for established players and new players in this market.

Check Complete Table of Content @ Table of Content @ https://www.advancemarketanalytics.com/reports/16856-global-cryopreservation-media-market

Country level Break-up includes:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Extracts from Table of Contents

Global Cryopreservation Media Market Research Report

Chapter 1 Global Cryopreservation Media Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Revenue (Value, Volume*) by Region

Chapter 5 Global Supplies (Production), Consumption, Export, Import by Regions

Chapter 6 Global Revenue (Value, Volume*), Price* Trend by Type

Chapter 7 Global Market Analysis by Application

.continued

This report also analyzes the regulatory framework of the Global Markets Cryopreservation Media Market Report to inform stakeholders about the various norms, regulations, this can have an impact. It also collects in-depth information from the detailed primary and secondary research techniques analyzed using the most efficient analysis tools. Based on the statistics gained from this systematic study, market research provides estimates for market participants and readers.

Key Development Activities:

On March 30, 2017, Osiris Therapeutics, Inc. (Pink Sheets: OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that it has developed cutting edge technology enabling the preservation of living cells and tissues at ambient temperatures. Osiris has developed Prestige Lyotechnology. Unlike all other known lyophilization methods, Prestige Lyotechnology enables the preservation of living cells within tissues while stored at ambient temperatures. This novel technology developed by Osiris will benefit the entire field of cellular therapies. It is expected to accelerate development, commercialization and widespread use of living cell and tissue therapies.

Buy full version of this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=16856

About Author:

Advance Market Analytics is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies revenues.

Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enable clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As.

CRAIG FRANCIS (PR & Marketing Manager)

[emailprotected]

Ph: +1 (206) 317 1218

Research On Global Stem Cell Cartilage Regeneration Market (impact of COVID-19), Analysis, Overview, Growth Forecast, Top key players Anika…

By adminAugust 1, 2020Stell Cell Research

Global Stem Cell Cartilage Regeneration Market 2020 Research Report

The Global Stem Cell Cartilage Regeneration Market 2020 Research Report is a professional and in-depth study on the current state of Stem Cell Cartilage Regeneration Market.

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Stem Cell Cartilage Regeneration Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

The key manufacturers covered in this report are:Anika Therapeutics,Zimmer Biomet,BioTissue Technologies,DePuy (Johnson & Johnson),Genzyme,CellGenix,EMD Serono,Sanofi Aventis,Smith & Nephew.

The final report will add the analysis of the Impact of Covid-19 in this report Stem Cell Cartilage Regeneration industry.

GET SAMPLE REPORT OF Stem Cell Cartilage Regeneration [emailprotected] https://www.reportsandmarkets.com/sample-request/global-stem-cell-cartilage-regeneration-market-professional-survey-2019-by-manufacturers-regions-countries-types-and-applications-forecast-to-2024?utm_source=bulletinline&utm_medium=46

Key questions answered in the report include:

What will the market size and the growth rate be in 2027?

What are the key factors driving the Global Stem Cell Cartilage Regeneration Market?

What are the key market trends impacting the growth of the Global Stem Cell Cartilage Regeneration Market?

What are the challenges to market growth?

Who are the key vendors in the Global Stem Cell Cartilage Regeneration Market?

What are the market opportunities and threats faced by the vendors in the Global Stem Cell Cartilage Regeneration Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

This unique market intelligence report from the author provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product as well as a profile of the companys diagnostics business.

The report, focuses on the global Stem Cell Cartilage Regeneration market, and answers some of the most critical questions stakeholders are currently facing across the globe. Information about the size of the market (by the end of the forecast year), companies that are most likely to scale up their competitive abilities, leading segments, and challenges impeding the growth of the market are given.

Analysis tools such as SWOT analysis and Porters five force model have been inculcated in order to present a perfect in-depth knowledge about Stem Cell Cartilage Regeneration market. Ample graphs, tables, charts are added to help have an accurate understanding of this market. The Stem Cell Cartilage Regeneration market is also been analyzed in terms of value chain analysis and regulatory analysis.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Stem Cell Cartilage Regeneration Market;

3.) The North American Stem Cell Cartilage Regeneration Market;

4.) The European Stem Cell Cartilage Regeneration Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2020-2027

14 Analysts Viewpoints/Conclusions

15 Appendix

If you have any special requirements, please let us know and we will offer you the report as you want.

ENQUIRE TO REPORT GET COMPLETE WITH DISCOUNT @ https://www.reportsandmarkets.com/sample-request/global-stem-cell-cartilage-regeneration-market-professional-survey-2019-by-manufacturers-regions-countries-types-and-applications-forecast-to-2024?utm_source=bulletinline&utm_medium=46

About Us:

Market research is the new buzzword in the market, which helps in understanding the market potential of any product in the market. This helps in understanding the market players and the growth forecast of the products and so the company. This is where market research companies come into the picture. Reports And Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world.

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)